Abstract

We previously showed that human apoC-III expression in transgenic mice causes hypertriglyceridemia due to the accumulation of enlarged very low density lipoprotein (VLDL)-like particles, with increased triglycerides and apoC-III and decreased apoE. In vivo turnover studies indicated the metabolic basis was decreased particle fractional catabolic rate. The presence of enlarged triglyceride-rich particles with prolonged residence time in plasma implied defective lipolysis, but in vitro these particles were good substrates for purified lipoprotein lipase (LPL). In the current study we further characterize the metabolic properties of these particles. We show that expression of a mouse apoC-III transgene can also cause hypertriglyceridemia with a similar accumulation of a VLDL-like particle with increased apoC-III and decreased apoE. A vitamin A fat tolerance test was used to show that MoCIIITg and HuCIIITg mice had similarly delayed clearance of triglyceride-rich postprandial particles. Thus, the previously observed hypertriglyceridemia caused by human apoC-III transgene expression was not due interspecies incompatibility but a property of apoC-III. In further experiments we showed VLDL from apoC-III transgenic mice interacted poorly with fibroblast lipoprotein receptors and this could be corrected by adding exogenous apoE. In addition, control VLDL interaction could be decreased by exogenous apoC-III. Moreover, the hypertriglyceridemia of HuCIIITg mice could be normalized by crossbreeding with HuETg mice. Thus, a functionally significant reciprocal relationship of apoC-III and apoE exists, presumably due to competition for space on the surface of triglyceride-rich lipoproteins. Finally, VLDL from HuCIITg and MoCIIITg mice showed decreased binding to heparin-Sepharose. This suggests and additional locus of the defect in these mice could potentially be in the binding of triglyceride-rich lipoproteins to heparan sulfate proteoglycan matrix on the surface of endothelial cells in which LPL is embedded. This could explain the predicted functional lipase deficiency in apoC-III transgenic mice based on the observation of a prolonged residence time of enlarged triglyceride-rich lipoproteins.

Highlights

  • We previously showed that human apoC-111expression in transgenic mice causes hypertriglyceridemiadue to the accumulation of enlarged very low density lipoprotein (VLDL)-like particles, with increased triglycerides and apoC111and decreased apoE

  • ApoC-I11 is a component of chylomicrons, very low density lipoproteins (VLDL) and high density lipoproteins (HDL)

  • The current report further characterizes the properties of triglyceride-richlipoproteins from apoC-I11transgenic mice

Read more

Summary

Introduction

We previously showed that human apoC-111expression in transgenic mice causes hypertriglyceridemiadue to the accumulation of enlarged very low density lipoprotein (VLDL)-like particles, with increased triglycerides and apoC111and decreased apoE. VLDL from HuCIIITg and MoCIIITg mice showed decreased binding to heparin-Sepharose This suggests an additional locus of the defect in these mice could potentially be in the binding of triglyceride-rich lipoproteins to heparan sulfate proteoglycan matrix on the surface of endothelial cells in which LPL is embedded. Transgenic mice expressing human apoC-111 (HuCIIITgmice) have elevated triglyceride levels due to the presence in plasma of enlarged triglyceride-rich lipoproteins with increased apoC-I11 and decreased apoE compared to controls [16,17,18]. Metabolic studies indicate these particles have a decreased fractional catabolic rate. Compatible with the notion that excess apoC-I11causes hypertriglyceridemia is the finding of low triglyceride levels and increased VLDL fractional catabolic rate in apoC-IIIdeficient knockout mice and humans with apoA-I/apoC-I11 deficiency [19, 20]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.